Clover Health Sees 33% Membership Growth and EBITDA Expansion Despite Challenges

Overview of Clover Health's Q3 2025 Earnings Call

During the recent earnings call, Clover Health Investments, Corp. (CLOV) provided insights into its performance for the third quarter of 2025. The company’s leadership emphasized a strong growth trajectory while acknowledging certain challenges that impacted their financial results.

CEO Andrew Toy opened the call by stating, "our growth engine is running well, and we remain focused on growing sustainably and profitably." However, he also acknowledged that the company "missed our targets on both overall adjusted EBITDA and stars." Despite these challenges, Toy expressed confidence in the company's ability to make quick adjustments and highlighted the success of Clover Assistant, which enabled the company to be "the top PPO in the country for the second year running on core HEDIS clinical quality scores."

Toy explained that the company experienced "broad systemic utilization pressure," which was compounded by its growth. This pressure affected 2025 adjusted EBITDA profitability, with a significant impact due to a "higher-than-expected proportion of new members" and the need to bring them under management more rapidly.

Membership Growth and Financial Performance

The company now expects to add roughly 44,000 gross new members within an expected year-end 2025 population of approximately 113,000 net members. While this growth may lead to near-term margin compression, it is anticipated to expand the base of profitable returning members in 2026.

CFO Peter Kuipers noted that despite increased utilization and margin pressure from a higher-than-expected mix of new members, the company delivered "insurance revenue of $479 million, an increase of 49% year-over-year." He highlighted that "returning member cohorts during the third quarter year-to-date 2025 period have generated approximately $217 of contribution profit per member per month as compared to a negative contribution of $110 per member per month for the new member cohorts."

Outlook and Guidance Adjustments

The company revised its full year 2025 outlook, increasing Medicare Advantage membership guidance to "average between 106,000 and 108,000 members, reflecting 33% growth year-over-year at the midpoint and continued intra-year growth this year." Insurance revenue guidance was also increased to a range of "$1.850 billion and $1.880 billion, reflecting year-over-year growth of 39% at the midpoint of the range."

Adjusted SG&A guidance was improved to "between $325 million and $335 million," representing "an approximate 400 basis point decrease or improvement year-over-year at the midpoint of the range." However, adjusted EBITDA and adjusted net income guidance were lowered to "between $15 million and $30 million" due to "a greater proportion of new members relative to our returning member base and higher utilization trends."

Financial Results and Key Metrics

Medicare Advantage membership grew 35% year-over-year to over 109,000 members, with insurance revenue increasing to $479 million, as reported by Kuipers. Year-to-date insurance revenue reached $1.4 billion, up 39% year-over-year.

Third quarter adjusted SG&A totaled $71 million or 14% of revenue, a 440 basis point improvement year-over-year. Year-to-date adjusted EBITDA and adjusted net income remained positive at $45 million and $44 million, respectively, despite pressures.

Both adjusted EBITDA and adjusted net income for the third quarter were $2 million, each down $17 million year-over-year. The company ended the quarter with cash, cash equivalents, and investments totaling $396 million on a consolidated basis.

Q&A Highlights

During the Q&A session, Jonathan Yong of UBS asked about utilization trends and whether there is a mispricing issue for 2026. Kuipers responded that "the underlying incurred cost trends, excluding pharmacy, is around 4%." He added that "that cost trend roughly is baked into the bid as well" and referenced additional tailwinds, such as the 4-star payment year and rate notices.

Yong further questioned BER stepping down from Q3 to Q4. Kuipers clarified, "we can refer back to the prepared remarks in my section where we talked about essentially intra-year PPV from the second half impacting the third quarter. So, the real -- the way to look at is really averaging out the first 3 quarters to get to kind of like a baseline expectation for the fourth quarter."

Analyst Sentiment and Management Tone

Analyst tone was neutral to slightly cautious, focusing on the impact of utilization trends, membership growth, and whether recent pressures are adequately priced into 2026 bids. Management maintained a confident and constructive tone in prepared remarks but acknowledged shortfalls, with Toy stating, "these misses aren't at all acceptable to us," and Kuipers emphasizing confidence "to deliver strong financial performance in the coming years."

Compared to the previous quarter, both analysts and management displayed increased concern over utilization pressures, with more direct questioning and defensive clarifications from management.

Quarter-over-Quarter Comparison

Guidance for adjusted EBITDA and net income was lowered this quarter, citing higher new member growth and utilization as primary drivers, compared to the previous quarter's more optimistic tone and higher profitability targets. Membership and revenue growth projections were both raised, while adjusted SG&A guidance improved, reflecting ongoing cost discipline.

Analyst focus shifted from broad industry pressures and product differentiation last quarter to utilization, pricing, and cost management this quarter. Management's confidence in long-term profitability and technology-driven care remains a constant theme, but the current quarter's tone is more cautious around near-term margin pressures and the need for operational adjustments.

Risks and Concerns

Management pointed to "broad systemic utilization pressure" and the challenge of integrating a "higher-than-expected proportion of new members." Pharmacy, dental, and supplemental benefit utilization were highlighted as notable cost drivers. Kuipers noted "abnormal activity within both dental and DME" and ongoing initiatives to optimize Part D and address these issues.

Guidance reflects expectations of continued elevated utilization in Q4 and the need to absorb a large group of new members from a smaller returning base.

Final Takeaway

Clover Health's Q3 2025 call underscored significant membership and revenue growth, driven by the continued rollout of Clover Assistant and expansion in priority markets. However, higher-than-anticipated new member growth and elevated utilization trends pressured margins and prompted downward guidance revisions for adjusted EBITDA and net income. Management remains confident that the foundation laid in 2025 will enable meaningful margin expansion and profitability in 2026, with technology-powered care models and disciplined cost management central to this strategy.